Biotech Values

[microcapfun]

Dynepo

>> was surprised when I saw your post on the discount. I remember back in the TKT days, Michael Astrue gave the impression a discount would be modest and it had some potential selling advantages the main being lack of evidence of pure red cell aplasia (though since it was rare hard to know for sure). If this still holds that and the price discount seems to be placing Shire in a strong position. FYI I think Dynepo was valued at about 450 million (if the TKT acquisition fell through that is what they would have paid for Dynepo alone). I believe their is a royalty still to be paid on Dynepo sales.<<


Cell Genesys no longer is due a royalty, though it is possible they will get a milestone associated with commercialization. Cell Genesys traded in future milestones for cash a while ago. Is someone else due a milestone??

I believe Dynepo is discounted because Amgen's EPO is longer lasting and there is also a cheaper generic EPO on the market or soon to be on the market.

(I think that's right, but I don't follow EPO closely.)

micro